Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy

Wiley - Tập 48 Số 11 - Trang 3224-3229 - 2003
Tjeerd van Staa1, Roland Laan2, I Barton3, Stanley Cohen4, Donald Reid5, Cyrus Cooper1
1University of Southampton, Southampton, UK
2University Medical Centre Nijmegen, The Netherlands
3Procter & Gamble Pharmaceuticals, Egham, UK
4St. Paul Medical Center, Dallas, Texas
5University of Aberdeen, Aberdeen, UK

Tóm tắt

AbstractObjectiveTo evaluate predictors of vertebral fractures, including a threshold for bone mineral density (BMD), in patients receiving oral glucocorticoids (GCs).MethodsData were obtained from 2 randomized clinical trials (prevention and treatment trials of risedronate) using similar methods, but different inclusion criteria were applied with regard to prior exposure to GCs. Predictors of vertebral fracture in the placebo group were identified using Cox regression with forward selection. The BMD threshold analysis involved a comparison of the 1‐year fracture risk in postmenopausal women receiving placebo in the GC trials with that in postmenopausal women not taking GCs in 3 other trials.ResultsThe study population comprised 306 patients with baseline and 1‐year followup data on vertebral fractures (111 receiving placebo and 195 receiving risedronate). In the placebo group, the statistically significant predictors of incident fracture were the baseline lumbar spine BMD (for each 1‐point decrease in T score, relative risk [RR] 1.85, 95% confidence interval [95% CI] 1.06–3.21) and the daily GC dose (for each 10‐mg dose increase, RR 1.62, 95% CI 1.11–2.36). In the BMD threshold analysis, compared with nonusers of GCs, patients receiving GCs were younger, had a higher BMD at baseline, and had fewer prevalent fractures; nevertheless, the risk of fracture was higher in the GC users compared with nonusers (adjusted RR 5.67, 95% CI 2.57–12.54). The increased risk of fracture was observed in GC users regardless of whether osteoporosis was present.ConclusionThe daily, but not cumulative, GC dose was found to be a strong predictor of vertebral fracture in patients receiving GCs. At similar levels of BMD, postmenopausal women taking GCs, as compared with nonusers of GCs, had considerably higher risks of fracture.

Từ khóa


Tài liệu tham khảo

10.18553/jmcp.2001.7.3.228

10.1093/qjmed/93.2.105

10.1007/s001980200108

10.1136/ard.54.1.49

10.1002/art.1780271205

10.1359/jbmr.2000.15.6.993

10.1093/rheumatology/39.12.1383

10.1136/thorax.56.4.279

10.1002/art.1780280402

10.1359/jbmr.2000.15.6.1001

10.1136/thx.46.11.803

10.1359/jbmr.2000.15.5.952

10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K

10.1359/jbmr.2000.15.6.1006

10.1056/NEJM200102013440503

10.1001/jama.282.14.1344

10.1007/s001980050010

10.1002/jbmr.5650080915

1996, SAS/GRAPH software: reference version 6

10.1097/00001648-199507000-00005

10.1001/archinte.160.19.2917

10.1136/ard.54.10.801

Johnell O, 2002, Oral corticosteroids increase fracture risk independently of BMD, Osteoporos Int, 13, S14

10.1172/JCI2799

Weinstein RS, 2002, Preservation of osteocyte viability by bisphosphonates contributes to bone strength in glucocorticoid‐treated mice independently of BMD: an unappreciated determinant of bone strength, J Bone Miner Res, 17, S156

10.1002/1529-0131(200107)44:7<1496::AID-ART271>3.0.CO;2-5

Bone and Tooth Society of Great Britain, 2003, Guidelines on the prevention and treatment of glucocorticoid‐induced osteoporosis

10.1007/s001980170046

Thông tin
Thông tin xuất bản

Wiley

Tập 48 Số 11

3224-3229

Thông tin tác giả